Nls Pharmaceutics Ag Stock Today
| NLSPW Stock | USD 0.01 0.0005 3.85% |
Performance9 of 100
| Odds Of DistressOver 70
|
NLS Pharmaceutics is selling for under 0.0135 as of the 18th of January 2025; that is 3.85 percent increase since the beginning of the trading day. The stock's lowest day price was 0.013. NLS Pharmaceutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of January 2021 | Category Healthcare | Classification Health Care |
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland. Nls Pharmaceutics is traded on NASDAQ Exchange in the United States.. More on NLS Pharmaceutics AG
Moving against NLS Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NLS Stock Highlights
| CEO President | Alexander MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | ||||
NLS Pharmaceutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NLS Pharmaceutics' financial leverage. It provides some insight into what part of NLS Pharmaceutics' total assets is financed by creditors.
| |||||
NLS Pharmaceutics AG (NLSPW) is traded on NASDAQ Exchange in USA. It is located in The Circle 6, Zurich, Switzerland, 8058 and employs 14 people. NLS Pharmaceutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.77 M. NLS Pharmaceutics classifies itself under Biotechnology sector and is part of Health Care industry.
NLS Pharmaceutics AG has accumulated about 145.4 K in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check NLS Pharmaceutics Probability Of Bankruptcy
NLS Pharmaceutics Historical Income Statement
NLS Stock Against Markets
NLS Pharmaceutics Corporate Management
| MBA IV | Interim Officer | Profile | |
| Dr LLM | G Counsel | Profile | |
| MA MBA | Interim Officer | Profile | |
| Silvia Panigone | Interim Officer | Profile | |
| Sandy MD | Interim Officer | Profile | |
| Sharon Keys | Head Affairs | Profile | |
| Geert MD | Interim Officer | Profile |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.